What value do JAK inhibitors have in treating rheumatoid arthritis?

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

COVID-19: combining antiviral and anti-inflammatory treatments

(2020) Justin Stebbing et al.   LANCET INFECTIOUS DISEASES

Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis

(2019) Peter C. Taylor et al.   Arthritis & Rheumatology

Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials

(2019) Wenhui Xie et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

(2019) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

059 A phase 3, randomised controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis

(2019) R van Vollenhoven et al.   RHEUMATOLOGY

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis

(2019) Christina Charles‐Schoeman et al.   Arthritis & Rheumatology

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

(2019) Roy M Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

(2019) Mark C. Genovese et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial

(2019) Roy Fleischmann et al.   Arthritis & Rheumatology

Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR)

(2019) Christophe RICHEZ et al.   JOINT BONE SPINE

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

(2018) Mark C Genovese et al.   LANCET

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study

(2018) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

(2018) Désirée van der Heijde et al.   CLINICAL RHEUMATOLOGY

Efficacy of baricitinib in the treatment of rheumatoid arthritis

(2017) Christophe Richez et al.   EXPERT OPINION ON PHARMACOTHERAPY

Immunopathogenesis of Rheumatoid Arthritis

(2017) Gary S. Firestein et al.   IMMUNITY

A Case Series on Patients on Tofacitinib in Combination With a Biologic

(2017) Nashla S. Barroso et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

(2017) Roy Fleischmann et al.   LANCET

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

(2017) Peter C. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET